Evidence map›Paper›PMID 42007379›Full record

ReviewGlobal heart2026

Advancing Lipid Management in Europe: Insights from the WHF Regional Roundtable Series and Country Case Studies.

Lana Raspail, Sean Taylor, Jeanine Roeters Van Lennep, José R González-Juanatey, Kausik K Ray, Raul D Santos

Abstract readReview
In one paragraph

Review in Global heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lana RaspailWorld Heart Federation, Switzerland.ORCID 0009-0001-9516-0829
Sean TaylorWorld Heart Federation, Switzerland.ORCID 0000-0002-5031-3588
Jeanine Roeters Van LennepDepartment of Internal Medicine, Erasmus MC Cardiovascular Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID 0000-0001-6870-9962
José R González-JuanateyCentro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, and University of Santiago de Compostela, Santiago de Compostela, Spain.ORCID 0000-0001-9681-3388
Kausik K RayImperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, School of Public Health Building, United Kingdom.ORCID 0000-0003-0508-0954
Raul D SantosHospital Israelita Albert Einstein and Heart Institute (InCor) University of Sao Paulo Medical School Hospital, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Elevated cholesterol remains a major modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD), yet lipid targets are unmet in many high- and very-high-risk individuals across Europe. This gap persists despite strong evidence, established guidelines, and effective therapies. To address this, the World Heart Federation (WHF) convened a Regional Europe Roundtable Series, bringing together clinicians, policymakers, researchers, and patient representatives. This review synthesises insights from meetings held in July and August 2025, alongside country case studies. Key barriers include low awareness, statin misinformation, fragmented care pathways, limited data systems, inequitable access to therapies, and inconsistent policies for familial hypercholesterolaemia detection and management. Despite these challenges, scalable solutions exist, including national strategies, screening programmes, digital referral systems, and integrated prevention initiatives. Strengthening policies, data systems, primary care capacity, public education, and equitable access to therapies will be essential to close the implementation gap in lipid management across Europe. Summary of challenges and solutions for lipid management in Europe, including unmet targets, fragmented care, limited data, and inequitable access, alongside proposed actions such as national strategies, screening programmes, digital tools, and improved therapy access.

Indexed as

Cardiovascular DiseasesLipidsEuropeHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl-CoA Reductase InhibitorsLipidscardiovascular diseasehealth policylipidsscreening

Identifiers

PMID42007379
PMCPMC13089369

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.